HESI Luncheon CITE Lecture (Monday, 14 March 2016, 12:45–1:45 PM, Hilton New Orleans Riverside, Jefferson Ballroom). Only a few spots remain! Register now for the HESI CITE lecture “Zika Virus, Host-Pathogen Evolution, and Transdisciplinary Solutions to Rapidly Emerging Public Health Crises.” Dr. Dawn Wesson, Associate Professor of Tropical Medicine at Tulane University, will provide background on the evolution of Zika and other similar viruses, its transmission and mechanism of action, and her thoughts on what diverse scientific disciplines will be required to control this rapidly spreading threat. To register for this lunchtime lecture, please click here.

Poster Presentation (Wednesday, 16 March 2016, 9:30 AM–12:45 PM, CC Exhibit Hall). The following poster will be presented: “In Vitro Fish Hepatic Metabolism: A Ring Trial to Evaluate Transferability, Intra- and Interlaboratory Reproducibility” (H.M. Peterson, M. Embry, K. Fay, M.J. Bernhard, I. Bischof, J.W. Davis, J. Domoradzki, M. Halder, X. Han, J. Hu, K.M. Johanning, H. Laue, D. Nabb, J. Nichols, C. Schlechtriem, H. Segner, L. van der Wal, and J. Weeks).

HESI is pleased to share a new book titled, Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers, which was co-edited by Dr. J. Eric McDuffie at Janssen, a long-time HESI member, along with several other HESI members and partners. Congratulations to these collaborators! Check out the book here.

• Male Reproductive Toxicology. The DART Technical Committee has launched a survey toward understanding the predictivity of adverse findings in nonclinical male fertility studies to clinical outcomes in men. The survey is open to all who are willing to contribute data. To learn more about or to participate in the survey, please contact Connie Chen ([email protected]). Survey responses will be accepted on a rolling basis through 30 June 2016.

• Nonclinical Neonatal Models.  The DART Technical Committee has formed a workgroup to understand the best use of nonclinical approaches for neonatal therapeutics.  In order to gain a better understanding of the scope and application of available approaches across industry, regulatory, and academic institutes, you are invited to submit your experience with current nonclinical models of drug development intended for neonatal pediatric diseases via an open survey. Contact Connie Chen ([email protected]) to learn more or to participate in the survey.